These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8353018)

  • 1. [The pharmacological therapy of glomerulonephritis].
    Cinotti GA; Comunian C
    Ann Ital Med Int; 1993; 8(2):108-12. PubMed ID: 8353018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current recommendations for the treatment of hypertension: are they still valid?
    Moser M
    J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunosuppressive therapy of glomerulonephritis--controlled studies].
    Ferrari P; Frey FJ
    Ther Umsch; 1993 Feb; 50(2):119-29. PubMed ID: 8456416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experience in the use of valsartan with the aim to inhibit progression of kidney failure in patients with chronic glomerulonephritis].
    Shvetsov MIu; Medvedeva TIu; Kozlovskaia NL; Miroshnichenko NG; Okonova EB; Shonichev DG; Rudenko TE; Stavrovskaia EV; Plieva OK
    Ter Arkh; 2001; 73(6):55-61. PubMed ID: 11521525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hypertension in renal parenchymal diseases].
    Iversen BM; Kvam FI; Svarstad E
    Tidsskr Nor Laegeforen; 1996 Jun; 116(17):2022-6. PubMed ID: 8766645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
    Dumoulin A; Hill GS; Montseny JJ; Meyrier A
    Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Post-transplant nephropathy and arterial hypertension].
    Oko A; Idasiak-Piechocka I; Czekalski S
    Przegl Lek; 2001; 58(9):859-63. PubMed ID: 11868248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Means for the inhibition of the nonimmune progression of nephritis].
    Tareeva IE; Kutyrina IM; Neverov NI
    Klin Med (Mosk); 1995; 73(3):80-3. PubMed ID: 8577123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease.
    Omata K; Kanazawa M; Sato T; Abe F; Saito T; Abe K
    Kidney Int Suppl; 1996 Jun; 55():S57-62. PubMed ID: 8743512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The kidneys and hypertension].
    Hausberg M; Mann J; Kühn K
    Dtsch Med Wochenschr; 2008 Sep; 133(37):1853-6. PubMed ID: 18770487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis].
    Kutyrina IM; Tareeva IE; Nosikov VV; Kamyshova ES; Gorashko NM; Chistiakov DA; Okonova EB; Troepol'skaia OV
    Ter Arkh; 1999; 71(6):30-4. PubMed ID: 10420452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic implications of recent megatrials in hypertension: in favor of new drugs.
    Volpe M; Tocci G
    J Nephrol; 2007; 20 Suppl 12():S12-8. PubMed ID: 18050137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension and progression of renal disease.
    Maschio G; Oldrizzi L; Marcantoni C; Rugiu C
    J Nephrol; 2000; 13(3):225-7. PubMed ID: 10928300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New results concerning the effectiveness of therapy of chronic glomerulonephritis. Results of cytostatics-anticoagulants-aggregation inhibitors, cystostatics-anticoagulants-aggregation inhibitors-prednisone and cystostatics-prednisone therapy, derived from a retrospective study].
    Sinn W; Ratner M; Tomilina N; Klinkmann H; Nizze H
    Z Urol Nephrol; 1986 Aug; 79(8):449-57. PubMed ID: 3535293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.